🧬 BRAF Cancer Research

BRAF is an oncogene that plays a critical role in cancer development, particularly in melanoma and colorectal cancer. When mutated, the BRAF gene produces proteins that can drive uncontrolled cell growth, making it one of the most frequently studied genetic alterations in cancer research. Understanding BRAF mutations has transformed how researchers identify cancer subtypes and develop targeted therapies, as tumors with specific BRAF mutations often respond differently to treatment than those without these changes.

As a biomarker, BRAF testing has become increasingly important in cancer diagnostics. Identifying BRAF mutations in a patient's tumor helps oncologists predict disease behavior, determine prognosis, and select the most effective treatment options. This precision medicine approach has led to the development of BRAF-targeted inhibitors and combination therapies that have significantly improved outcomes for certain cancer patients. Ongoing research continues to explore how BRAF mutations interact with other genetic changes and how resistance to BRAF-targeted treatments can be overcome.

This page brings together the latest peer-reviewed research on BRAF mutations, biomarker testing, and diagnostic advances in cancer care. Whether you're seeking to understand your own test results or learn about emerging research directions, the articles below represent current scientific findings from leading cancer research institutions worldwide.